cobenfy bristol myers squibb - Search News

Bristol Myers Squibb, schizophrenia

CNBC on MSN · 2d

Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the latter part of the year.

NBC Los Angeles · 4d

Bristol Myers Squibb CEO describes new drug for treating schizophrenia

Bristol Myers Squibb CEO Chris Boerner described Cobenfy, a new drug to treat schizophrenia and may also help with bipolar disorder and Alzheimer’s disease.

Business Insider · 2d

Positive Outlook for Bristol-Myers Squibb with Promising Market Access and Societal Benefits of Cobenfy

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target

Hosted on MSN · 3d

Bristol Myers Says New Schizophrenia Drug Off to Strong Start

Bristol Myers Squibb Co. said its new schizophrenia drug is off to a better start than similar recently launched treatments, in an early sign that its $14 billion purchase of Karuna Therapeutics is paying off.

FDA approves first new schizophrenia drug in more than 30 years

The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.

3d

Bristol Myers CEO says new drug Cobenfy effective in schizophrenia, CNBC reports

Bristol Myers (BMY) new psychiatric drug Cobenfy is effective in treating schizophrenia without “the serious side effects’ of other older ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results